🇺🇸 FDA
Patent

US 10709703

2,4-pyrimidinediamine compounds and their uses

granted A61KA61K31/505A61K31/506

Quick answer

US patent 10709703 (2,4-pyrimidinediamine compounds and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/505, A61K31/506, A61K31/519, A61K31/5377